ArticleNew microbes and new infections2025
Comparative analysis of dominant gut microbiota in Inflammatory Bowel Disease patients and healthy individuals: A case-control study.
Article in New microbes and new infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Viral-Gut Microbiota Interactions: Implications for the Gut Mucosa in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Review
- Dietary theabrownins alleviate age-related declines in productive performance and egg quality by improving intestinal health in laying hens.Journal of animal science and biotechnology · 2026Article
- Psoriatic Arthritis: Developments in 2025.Mediterranean journal of rheumatology · 2026Review
- Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.Digestive diseases and sciences · 2026Review
- Importance of human microbiome: an update.Frontiers in microbiomes · 2026Review
- Integrin α4β7: Pathogenic Roles in Metabolic and Inflammatory Diseases and Translational Therapeutics.Journal of inflammation research · 2026Review
- Gut microbiota and bile acids profiles study of ulcerative colitis and Crohn's disease patients.Frontiers in microbiology · 2026Article
- Disruption of intestinal barrier and immune homeostasis links gut microbiota dysbiosis to aggravated experimental autoimmune myasthenia gravis.Frontiers in cellular and infection microbiology · 2026Article
- Isolation and characterization of a novel lytic bacteriophage forGut microbes reports · 2026Article
- Exploring the etiology of colitis: insights from gut microbiota research.Gut microbes · 2025Review
- Lactobacillus johnsonii alleviates experimental colitis by restoring intestinal barrier function and reducing NET-mediated gut-liver inflammation.Communications biology · 2025Article
- Novel TLR2 agonist Amuc_C derived fromAnimal cells and systems · 2025Article
- Integrated gut microbiome and metabolomics analysis reveals microbial-metabolic cross-talk in allergic rhinitis.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammation in the gut might be linked to microbiota dysbiosis. Objective: This study aimed to investigate alterations in the gut microbiota composition of adult IBD patients compared to healthy controls. Methods: This case-control study investigated the relationship between faecal microbiota composition and IBD in adults. Real-time qPCR analysis using bacterial 16S rRNA gene quantified the abundance of six key bacterial groups (Firmicutes, Results: Real-time qPCR revealed significant differences ( Conclusion: This study identified significant alterations in gut microbiota composition in adult IBD patients compared to healthy controls, with notable differences in the abundance of specific bacterial groups. These findings suggest that gut microbiota dysbiosis may play a critical role in IBD pathogenesis. The identification of specific bacterial imbalances provides a foundation for developing microbiota-based therapies, such as probiotics, prebiotics, and fecal microbiota transplantation, as potential interventions for restoring microbial balance and mitigating disease progression. Further research is needed to translate these insights into targeted therapeutic strategies and to explore their effectiveness in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.